FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, in particular, oncology for the treatment of bladder cancer, as well as the method, device and drug, used in order to achieve a sustained concentration of oxaliplatin in urine in the bladder sufficient to produce a therapeutic concentration of oxaliplatin in bladder tissue. To do this, the patient is intravesically injected with an intravesical device for the continuous release of oxaliplatin in a dosage of 1 to 100 mg per day for 1–14 days. Oxaliplatin may be in solution or non-liquid dosage form comprising granules, tablets, capsules or a combination thereof. In addition, oxaliplatin can enter the bladder from the coating substance applied to the inner surface of the bladder.
EFFECT: group of inventions ensures continuous release of oxaliplatin into the bladder over an extended period of time.
17 cl, 12 dwg, 2 ex
